NLRP3 and central nervous system cancer: Simultaneously, we demonstrated that inhibiting p-STAT3 through EZH2 enhances NLRP3 inflammasome activity, promoting glioma pyroptosis and the expression of inflammatory factors IL-1β and IL-18 (Fig. 7).